Plain-English translation of NCT05510817 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study wants to understand what factors predict how your relapsing-remitting MS will progress and how you'll respond to treatment. Researchers will use a combination of brain scans, thinking and memory tests, and nerve function tests to find patterns that can help doctors predict your individual disease course. The goal is to help neurologists better understand who will improve, stay stable, or worsen over time—so they can tailor treatment more effectively for each patient.
Doctors currently struggle to predict which MS patients will improve with treatment and which will decline. Recent research suggests that cognitive changes (thinking and memory problems) in MS don't always get worse over time as doctors once thought—the patterns are more complex. This study aims to identify reliable markers that can help predict your personal disease trajectory, so treatment decisions can be more personalized.
If you join, you will visit the research center once a year for a full day of testing. Each visit includes a brain MRI scan, thinking and memory tests, nerve function tests, blood work, and questionnaires about your symptoms and quality of life. This continues yearly from when you start your new treatment, so you might participate for several years. The study tracks how you change over time to help identify which factors predict how your MS will evolve.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Belgium
Sponsor
University Hospital of Mont-Godinne
Collaborators
Saint-Luc University Hospital
Enrollment target
~50 participants
Started
June 2022
Primary completion
June 2026
Age range
18 Years – 50 Years
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Frédéric London, MD
University Hospital Mont-Godinne